Samsung Biologics Co.,Ltd. (207940.KS), a contract development and manufacturing organization, on Wednesday reported higher earnings for the first quarter, supported by revenue growth.
Operating profit increased to KRW 580.8 billion from KRW 430.2 billion last year.
EBITDA (earnings before interest, taxes, depreciation and amortization) rose to KRW 675.3 billion from KRW 514.6 billion a year earlier.
Revenue grew to KRW 1.257 trillion from KRW 999.5 billion in the previous year.
Looking ahead, the company said it is on track to meet its full-year outlook.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.